BenevolentAI Investor Presentation Deck

H1 2022 Highlights 1 Continued progress across in-house pipeline 2 3 5 6 7 Consistent delivery in collaboration with AstraZeneca - non-commercial collaborations progressing Full FDA approval of COVID-19 treatment first identified by BenevolentAl Continuous enhancement of the Benevolent Platform™ Completed Business Combination/listed Amsterdam EuroNext - raised gross proceeds of €225m Strengthened Board of Directors and Leadership Building Business Operations capability for long term success Benevolent 16

View entire presentation